Document is current
Any future updates will be listed below
-
Authors
Li, Weikun http://orcid.org/0000-0002-9525-9001
Yalcin, Murat http://orcid.org/0000-0002-5600-8162
Bharali, Dhruba J. http://orcid.org/0000-0001-8539-1909
Lin, Qishan http://orcid.org/0000-0002-1756-1432
Godugu, Kavitha http://orcid.org/0000-0002-1844-7041
Fujioka, Kazutoshi http://orcid.org/0000-0001-8534-8687
Keating, Kelly A. http://orcid.org/0000-0002-1767-6379
Mousa, Shaker A. http://orcid.org/0000-0002-9294-015X
-
Funding
Funding for this research was provided by:
This work was supported in part by the Pharmaceutical Research Institute (PRI) and in part by a grant from NanoPharmaceuticals LLC (Rensselaer, NY, USA).
- License Information
-
More Information
Article History
Received: 14 May 2018
Accepted: 22 May 2019
First Online: 21 June 2019
Change Date: 3 October 2023
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1038/s41598-023-43642-5
Competing Interests
: S.A.M. holds stock in NanoPharmaceuticals LLC, which is developing anticancer drugs. K.A.K. is a paid consultant of NanoPharmaceuticals LLC. All other authors declare no competing interests.
